B
Brian I. Rini
Researcher at Vanderbilt University Medical Center
Publications - 652
Citations - 49231
Brian I. Rini is an academic researcher from Vanderbilt University Medical Center. The author has contributed to research in topics: Renal cell carcinoma & Sunitinib. The author has an hindex of 89, co-authored 608 publications receiving 38953 citations. Previous affiliations of Brian I. Rini include University of California, San Francisco & Cleveland Clinic.
Papers
More filters
Journal ArticleDOI
Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma
Brian I. Rini,Sabina Signoretti,Toni K. Choueiri,David F. McDermott,Robert J. Motzer,Saby George,Thomas Powles,Frede Donskov,Scott S. Tykodi,Sumanta K. Pal,Saurabh Gupta,Chung-Wei Lee,Ruiyun Jiang,Nizar M. Tannir +13 more
TL;DR: In this article , first-line nivolumab plus ipilimumab (NIVO+IPI) provided efficacy benefits over sunitinib (SUN) in patients with intermediate/poor-risk sRCC at 42 months minimum follow-up in the CheckMate 214 trial.
Journal ArticleDOI
A phase II trial of low-dose interleukin-2 (IL-2) and bevacizumab in patients with metastatic renal cell carcinoma (mRCC)
Jorge A. Garcia,Brian I. Rini,Tarek Mekhail,Pierre L. Triozzi,Paul Elson,Cheryl Nemec,Ronald M. Bukowski +6 more
TL;DR: To further evaluate the clinical and immunomodulatory effect of low-dose IL-2 and bevacizumab in mRCC, a phase II trial was conducted and a Simon 2 stage phase II design was employed to test the hypothesis of a 40% improvement in the 3-month PFS vs. historical IL- 2-treated controled patients.
Journal ArticleDOI
Outcomes in Black and White Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors: Insights From Two Large Cohorts.
Dominick Bossé,Dominick Bossé,Wanling Xie,Xun Lin,Ronit Simantov,Aly-Khan A. Lalani,Jeffrey Graham,J. Connor Wells,Frede Donskov,Brian I. Rini,Benoit Beuselinck,Ajjai Alva,Aaron R. Hansen,Lori Wood,Denis Soulières,Christian Kollmannsberger,Francois Patenaude,Daniel Y. C. Heng,Toni K. Choueiri,Rana R. McKay +19 more
TL;DR: Black patients had more IMDC risk factors and worse outcomes with first-line tyrosine kinase inhibitors versus white patients and race was not an independent predictor of OS.
Journal ArticleDOI
Mp86-17 the 2017 american joint committee on cancer eighth edition cancer staging manual: changes in staging guidelines for cancers of the kidney, renal pelvis and ureter, bladder, and urethra
Dennis J. Robins,Alexander C. Small,Mahul B. Amin,Bernard H. Bochner,Sam S. Chang,Toni K. Choueiri,Jason A. Efstathiou,Mary Gospodarowicz,Donna E. Hansel,Patrick A. Kenney,Badrinath R. Konety,Jaime Landman,Cheryl T. Lee,Bradley C. Leibovich,Elizabeth R. Plimack,Victor E. Reuter,Brian I. Rini,Srikala S. Sridhar,Walter M. Stadler,Satish K. Tickoo,Raghunandan Vikram,Ming Zhou,James M. McKiernan +22 more
TL;DR: In this paper, the authors compared treatment patterns before and after introduction of the GPS assay within 6 VAMCs and found that GPS may be a useful tool to refine risk assessment of PCa and to increase the already high rates of AS among clinically and biologically low risk patients, regardless of their race and AO exposure.
Journal ArticleDOI
Impact of bone and liver metastases (BM, LM) in patients with metastatic renal cell carcinoma (mRCC) treated with molecularly targeted agents (MTAs): Results from the International mRCC Database Consortium (IMDC).
Rana R. McKay,Nils Kroeger,Wanling Xie,Jae-Lyun Lee,Jennifer J. Knox,Georg A. Bjarnason,Mary J. MacKenzie,Lori Wood,Sandy Srinivas,Ulka N. Vaishampayan,Sun Young Rha,Sumanta K. Pal,Frede Donskov,Srinivas K. Tantravahi,Brian I. Rini,Daniel Y.C. Heng,Toni K. Choueiri +16 more
TL;DR: BM and LM in mRCC patients have significant clinical relevance and may possibly be used for risk-stratification of patients with mR CC.